This week, Sarepta Therapeutics Inc (NASDAQ:SRPT) dosed its first patient with commercial Exondys 51 (eteplirsen), the biotech firm’s intravenous infusion Duchenne muscular dystrophy …
Tuesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) and Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a deal that will grant Sarepta European commercialization rights for Summit’s …
Yesterday, Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a collaboration and license agreement, which will grant Sarepta Therapeutics Inc (NASDAQ:SRPT) European Union commercialization rights …
On Wednesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has dosed the first patient in the Phase III ESEENCE trial for patients with …
Sarepta Therapeutics Inc (NASDAQ:SRPT) and Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD).
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced yesterday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta over an intellectual property and …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued …
On Monday, September 19th, the FDA granted accelerated approval to Sarepta Therapeutics Inc (NASDAQ:SRPT) pipeline drug eteplirsen (Exondys 51), designed to treat exon …
